Compare Globus Medical Inc. Class A Common Stock (GMED) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs PubMatic Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while PubMatic Inc trades at $17.61 (market cap $860.90M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 11.9× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and PubMatic Inc for 40 Days on average.
| GMED | PUBM | |
|---|---|---|
Market Cap | $10.25B | $860.90M |
Volume | 1,108,124 | 528,167 |
Sector | Health | Technology |
52-Week High | $96.82 | $19.18 |
52-Week Low | $58.33 | $6.28 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $9.76B | $764.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PUBM trades at $17.64, down 4.75% today but maintains strong technical momentum with bullish moving average signals. The company reported three consecutive quarterly EPS beats despite negative annual net income margins. Recent Q2 2026 results showed 10.5% revenue growth and a significant EPS beat of $0.12 versus $0.03 expected, driven by mobile app and CTV segment strength.
Wall Street maintains bullish sentiment with 11 buy ratings and a $19.89 consensus target, representing 13% upside. Key risks include CFO transition uncertainty and competitive ad-tech landscape pressure. The stock's premium valuation (P/E 132) requires continued execution on AI-driven growth initiatives to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
